Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Florence's Uffizi Gallery moves treasures to safety after cyberattack - 2Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- 3An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
- 4Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- 5Far-right German youth group delegates seek deportations, remigration
- Iran begins cloud seeding to induce rain amid historic drought
- A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- Vote in favor of the handheld vacuum that you love for its strong attractions!
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- The most effective method to Explore Moral Situations in Brain research with Your Certification
- First part of major new German-Danish tunnel cleared for lowering
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Grasping the Basics of Business Land Regulation
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
